Based on the ASCO/CAP 2018 guidelines, HER2 scores 0 and 1+ are considered HER2-negative, whereas a HER2 score of 3+ indicates HER2-positive BC that requires HER2-targeted treatment. This evidence concerns the gene ERBB2 and breast cancer.